Adjuvant taxotere [docetaxel] in patients with high risk prostate cancer post prostatectomy and radiation.
Phase of Trial: Phase II
Latest Information Update: 12 Jun 2012
At a glance
- Drugs Docetaxel (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 12 Jun 2012 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
- 04 May 2012 Actual patient number is 13 according to ClinicalTrials.gov.